- 全部删除
- 您的购物车当前为空
PD 130908 is an analogue of RSU 1069 with effective hypoxic cytotoxin, but less potent than RSU 1069. Toxicity toward hypoxic tumor cells in vivo is demonstrated by clamping tumors (for 60 min) following administration of PD 130908. Systemic toxicity is substantially reduced following oral drug administration. Further, doses achievable following fractionated drug treatments are sufficiently high to produce significant levels of radiosensitization.
PD 130908 is an analogue of RSU 1069 with effective hypoxic cytotoxin, but less potent than RSU 1069. Toxicity toward hypoxic tumor cells in vivo is demonstrated by clamping tumors (for 60 min) following administration of PD 130908. Systemic toxicity is substantially reduced following oral drug administration. Further, doses achievable following fractionated drug treatments are sufficiently high to produce significant levels of radiosensitization.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | PD 130908 is an analogue of RSU 1069 with effective hypoxic cytotoxin, but less potent than RSU 1069. Toxicity toward hypoxic tumor cells in vivo is demonstrated by clamping tumors (for 60 min) following administration of PD 130908. Systemic toxicity is substantially reduced following oral drug administration. Further, doses achievable following fractionated drug treatments are sufficiently high to produce significant levels of radiosensitization. |
别名 | PD-130908, PD130908 |
分子量 | 358.03 |
分子式 | C8H14Br2N4O2 |
CAS No. | 131505-02-7 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容